Company intelligence / Profile preview

REGiMMUNE

Ownership: Private
Development stage: Other

Overview

The company has completed a Phase 1/2a study for RGI-2001 in 2015 and started a Phase 2 study in November 2019[1]. They also have a Haplo Peripheral Blood SCT Phase 1 study for RGI-2001 that started in August 2020[1].

Therapeutic areas: OncologyImmunologyRare DiseasesEndocrinology
Modalities: ImmunotherapiesBiologicsAntibodies
Industry: Biotech

Drug pipeline

7 assets

RGI-2001

6 more assets in the full pipeline.

Partnerships

JDRFPfizer (research agreement for Type 1 diabetes in 2015)[1]

Beyond the preview

Go deeper on REGiMMUNE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGiMMUNE.